Competition record
Eli Lilly
Deep profile · 0 linked library matters
Eli Lilly sells Mounjaro and Zepbound for diabetes and weight loss and is also a major insulin supplier through Humalog. It races Novo Nordisk for the same specialists, the same pen capacity, and the same payer formularies.
Overview
Lilly is based in Indianapolis and built tirzepatide into Mounjaro for type 2 diabetes and Zepbound for obesity. Novo Nordisk's Ozempic and Wegovy are the products endocrinologists compare against it week by week.
The company still sells a large insulin franchise, including Humalog, so the same payers negotiate basal and mealtime insulin and the newer GLP-1 drugs with one manufacturer. Trulicity, an older dulaglutide pen, remains in that diabetes portfolio as tirzepatide takes share.
Lilly has been adding manufacturing in Indiana and North Carolina because fill-finish, not the prescription pad, has limited how fast Zepbound can ship. Pharmacy benefit managers decide which of the two GLP-1 brands sits on the preferred tier.
Competition footprint
Tirzepatide patents and pen patents set the clock for anyone else who wants this incretin class.
Insulin and GLP-1 volume both depend on formulary tiering at CVS Caremark, Express Scripts, and OptumRx.
New fill-finish sites in Indiana and North Carolina are the capacity Lilly's wholesale customers are waiting on.
Consumer & business angle
A person with diabetes may face both an insulin copay and a separate coverage fight for a weight-loss indication.
Wholesalers and pharmacies allocate scarce pens, so a covered prescription can still go unfilled.
What to watch
- Whether employer plans add Zepbound for obesity or keep coverage limited to diabetes labels.
- Ramp-up at the Indiana and North Carolina plants, and any insulin-pricing commitment that changes the Humalog book.
Markets
GLP-1 medicines · insulin · diabetes drugs
Also known as: lilly, mounjaro, zepbound, humalog
Conduct themes
Linked cases in the library
No linked matters in the current library yet. The narrative above is still a market-power primer — check primary sources for live disputes.